The following editorial from Mike Lee, COO of Evergreen Health, Secretary of RWC-340B was posted in the New York Daily News on September 16, 2020
Over
Thanks to efforts by RWC-340B members and other covered entity advocates, 243 members of the House of Representatives (174 Democrat and 69 Republican members) signed
Today, RWC-340B submitted to a letter to Secretary of the U.S. Department of Health and Human Services (HHS) Alex Azar requesting that HHS initiate enforcement
In a notice sent to covered entities and other 340B program participants, Eli Lilly and Co. (Lilly) announced that, effective September 1, 2020, it is
On August 26, Second Sight Solutions, the owner of the 340B ESP™ platform, hosted the second in a series of webinars on 340B ESP™. The
Here is a press statement from RWC-340B president Shannon Stephenson regarding the recent actions taken by drug manufacturers Lilly, Novartis, Merck, Sanofi, and Astra Zeneca.
This week, Kalderos announced that it is launching its new “340B Pay” platform which, if implemented, would fundamentally change how the 340B drug discount program
Earlier this week a third drug manufacturer, Novartis Pharmaceuticals, sent letters to 340B covered entities with contract pharmacy arrangements stating that beginning October 1, 2020,
Today, Astra-Zeneca joined other manufacturers in announcing that it would no longer honor all contract pharmacy arrangements. Astra-Zeneca sent letters to 340B covered entities informing
On July 29, Reps. Doris Matsui (D-CA) and Chris Stewart (R-UT) introduced a bill that would protect 340B hospitals from losing their covered entity status
